Company news
Liquidia Corporation news in 2023
Liquidia Corporation's news releases, calls and decks from 2023, newest first.
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
December 19, 2023
Liquidia Announces Pricing of Public Offering of Common Stock
December 11, 2023
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 6, 2023
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
October 30, 2023
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
September 24, 2023
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
September 5, 2023
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 9, 2023
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
August 2, 2023
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
July 26, 2023
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
July 23, 2023
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
June 27, 2023
Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference
May 30, 2023
Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
May 18, 2023
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 3, 2023
Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference
May 1, 2023
Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023
April 26, 2023
Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications
April 2, 2023
Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023
March 8, 2023
Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)
February 1, 2023
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 1, 2023
Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million
January 8, 2023